Daratumumab + lenalidomide + dexamethasone

Daratumumab, lenalidomide and dexamethasone at a glance

DRd contains three active medicines. Daratumumab is a targeted antibody treatment, lenalidomide is an immunomodulatory medicine, and dexamethasone is a corticosteroid with an important role in myeloma treatment. The steroid is part of the regimen. This guide does not describe a steroid-free daratumumab–lenalidomide schedule.

Daratumumab is known as Darzalex. Darzalex Faspro is the US name for the under-the-skin formulation containing daratumumab and hyaluronidase. Revlimid is a lenalidomide brand; other products are available in some countries. Brand names do not confirm local availability or interchangeability.

Treatment combines hospital visits with a home medicine calendar. The number of hospital visits usually decreases over time. Monitoring and supportive medicines are part of the treatment plan.

How the combination works

Myeloma affects plasma cells, a type of white blood cell made in bone marrow. Abnormal plasma cells can affect blood-cell production, bones and kidneys. Treatment aims to control these cells and the problems they cause.

Daratumumab attaches to a protein called CD38 on myeloma cells. This helps immune defences recognise and destroy them. Although it uses the immune system, it is different from checkpoint inhibitors such as pembrolizumab.

Lenalidomide changes several signals involved in myeloma-cell growth and immune activity. Dexamethasone helps kill myeloma cells and reduce inflammation. Together, the medicines act in complementary ways. They can also affect normal cells, explaining the need to check blood counts and other body functions.

Your haematologist will explain the expected benefit and alternatives. The aim is usually sustained disease control; individual responses vary.

How the team decides whether it is suitable

DRd is an established option for some adults with newly diagnosed myeloma who are not suitable for an autologous stem-cell transplant, which uses their own stem cells. It is also used for selected people whose myeloma has returned or resisted treatment after at least one previous treatment.

Previous exposure to daratumumab or lenalidomide, and whether the myeloma resisted those medicines, matter. Treatment selection also considers kidney function, infections, frailty, blood counts and other illnesses. DRd is one option among several; the presence of myeloma alone does not determine the best regimen.

Transplant and maintenance schedules may differ. Do not substitute this calendar for another regimen with similar drug names.

Before treatment starts

Blood tests check blood counts, kidney and liver function, calcium and other blood salts. The team assesses myeloma proteins and may arrange scans or other disease measurements. Tell them about diabetes, previous blood clots, bleeding, recurrent infections, breathing problems, mood disorders and all medicines you take.

Hepatitis B screening is needed before daratumumab. An old infection can become active again even if you felt well for years. A positive result may require specialist advice, preventive treatment or additional monitoring.

The blood bank should perform blood-group and antibody testing before your first daratumumab dose. Daratumumab can interfere with tests used to match donor blood. It does not change your blood group, and transfusion remains possible when the laboratory knows about treatment.

Discuss pregnancy prevention before receiving lenalidomide. Ask about medicines to prevent shingles or other infections and a personalised plan to reduce blood-clot risk. Do not buy aspirin or another blood thinner for this purpose yourself.

Obtain your calendar, 24-hour contact number, alert card and prescription-supply plan.

How treatment is taken or given

The treatment calendar

A usual DRd cycle lasts 28 days. Daratumumab is often given weekly for cycles 1–2, every two weeks for cycles 3–6, and every four weeks from cycle 7. Lenalidomide is usually taken on days 1–21, followed by seven days without it. Dexamethasone is commonly weekly or divided across specified days. Follow your own calendar, especially after a delay.

Daratumumab at hospital

An injection under the skin of the abdomen usually takes about three to five minutes, but assessment, preparation and observation make the visit longer. Intravenous daratumumab is an alternative; the infusion takes longer, particularly at the beginning. The formulations have different doses and administration instructions. Your hospital selects the appropriate product.

You receive medicines before administration to reduce reactions, typically a steroid, an antihistamine and paracetamol. Additional medicines afterwards may be prescribed. The steroid given at hospital may count towards that day's dexamethasone: confirm this to avoid taking a duplicate dose at home. Observation is especially important after the first treatment.

Capsules and tablets at home

Take lenalidomide at a consistent time, with or without food. Swallow capsules intact with water. Do not open, crush or chew them. Tell the pharmacist if swallowing is difficult. Kidney function can substantially change the prescribed dose, so someone else's capsule strength is not a useful comparison.

Take dexamethasone on the written days, generally in the morning with food. It is not automatically a daily medicine in DRd. If the schedule is split across two days, follow that instruction exactly. Do not change or abruptly stop a continuing steroid course without advice.

Missed doses, vomiting and storage

For once-daily lenalidomide, the US patient instructions allow a missed dose within 12 hours of its usual time; after more than 12 hours, skip it. Never double a dose. Follow the leaflet supplied with your product and ask the pharmacist if the timing is unclear.

If you miss dexamethasone or vomit a dose, contact the team for instructions. Do not automatically repeat any oral dose after vomiting. Keep medicines in their original packaging, away from children; return unused capsules to the pharmacy.

Monitoring and checking response

Regular blood tests track infection-fighting cells, haemoglobin, platelets, kidney and liver function, blood salts and glucose. Tests may be more frequent early in treatment or after a problem. A dose can need adjustment even when you feel well.

Myeloma blood or urine markers, symptoms and sometimes scans help assess response. Daratumumab can also interfere with some tests measuring myeloma antibodies; specialist laboratories can take this into account. One result should be interpreted with the rest of your assessment.

Bring your medicine list and symptom record. Note when symptoms began and their effect on eating, sleep or activity.

A prescribed reduction, break or extra supportive medicine can make treatment more manageable. Ask which medicines change, when to repeat tests and who will confirm restarting. A delay alone does not establish that treatment has stopped working.

Common side effects and practical care

The effects below are commonly reported in DRd patient information or combination studies. Their frequency varies with formulation, previous treatment and the population studied. “Common” does not mean mild, and a serious problem is not necessarily rare. You are unlikely to experience everything listed.

Low white cells and infections

Neutropenia means fewer infection-fighting white cells. Infections, including chest infections, are important with DRd. Report a new cough, sore throat, burning urine, shivering or suddenly feeling unwell. Do not wait for a blood-count result before seeking advice. Steroids can make signs of infection less obvious.

Wash hands regularly, practise food safety and avoid close contact with people who are actively unwell. Keep a thermometer available. Take prescribed antiviral or other preventive medicines as directed; they reduce particular risks but cannot prevent every infection. The temperature and urgent-contact advice is in the next urgent-help section.

Anaemia, bruising and bleeding

Low red cells can cause unusual tiredness, breathlessness, dizziness or a racing heart. Low platelets can cause easy bruising, nosebleeds, bleeding gums or small red or purple spots. Report these changes promptly; blood tests guide whether you need a treatment adjustment, transfusion or other support.

Tell the team if you are also taking a clot-prevention medicine. Do not stop it or add painkillers without advice. Use gentle oral care and avoid activities likely to cause injury when the team says your platelets are low.

Tiredness and reduced stamina

Fatigue may not disappear after a night's sleep. Plan essential tasks for your better periods, break activities into smaller steps and accept help with transport or meals. Gentle movement can help, but myeloma-related bone problems may limit which exercise is suitable. Ask for an individual activity plan.

Report a sudden deterioration or tiredness that prevents basic activities. Anaemia, infection, poor sleep, pain and reduced food intake may contribute and can need treatment. Keeping a short energy-and-sleep diary can help the team understand the pattern.

Diarrhoea and constipation

Report new or persistent loose stools and record how often they occur compared with normal. Drink regularly within any kidney or heart fluid restriction. Use anti-diarrhoea medicine according to your team's instructions. Blood in stools, fever, dizziness or inability to drink needs prompt assessment; infection and other causes must be considered.

For constipation, gentle movement, suitable fluids and an agreed bowel plan may help. Ask early about laxatives rather than waiting until you are very uncomfortable. Avoid enemas or suppositories unless your team approves them. Severe abdominal pain, swelling or vomiting needs assessment instead of simply taking more laxative.

Nausea, appetite, taste and mouth discomfort

Take prescribed anti-sickness medicine as instructed. Smaller meals, simple foods and frequent sips can be easier than a large meal. Report repeated vomiting, weight loss or difficulty maintaining fluids. Ask for dietitian support if eating becomes a daily struggle.

Clean your mouth gently with a soft toothbrush. Tell the team about ulcers, white patches, dry mouth or painful swallowing. Soft foods and recommended mouth-care products may improve comfort. Avoid harsh mouthwashes or foods that sting; soreness should be treated, not accepted as a reason to stop eating.

Cramps, aches, swelling and skin changes

Muscle cramps, joint or back discomfort, ankle swelling and itchy skin can occur. Mention new symptoms, particularly swelling that increases quickly or affects only one leg. The team may review blood salts, kidney function, medicines and the cause of pain. Use only approved pain relief.

Gentle moisturiser may help dry skin. Report any new rash before it becomes extensive. Numbness or tingling also deserves attention: tell the team if it affects walking or buttons. Protect numb feet, reduce trip hazards and avoid burns from hot water or cooking surfaces.

Dexamethasone: sleep, mood and blood sugar

Steroid days may bring extra energy, irritability, increased appetite, indigestion or difficulty sleeping. Take the dose with food at the agreed morning time and keep a regular bedtime routine. Tell the team when symptoms interfere with relationships or rest; steroid doses can sometimes be adjusted.

Dexamethasone can raise blood sugar even without previous diabetes. Report marked thirst, frequent urination or blurred vision. If you have diabetes, ask when to check glucose and how medicines should be adjusted on steroid and non-steroid days. Do not make those adjustments without a plan.

Important side effects to recognise

This section includes less frequent complications and problems whose frequency cannot reliably be stated for every DRd schedule. It is organised by the action needed, rather than implying that all these problems are rare.

Administration reactions and severe skin reactions

Daratumumab reactions are most likely around early doses. Tell the nurse immediately about flushing, itching, shivering, wheezing, chest tightness, dizziness or swelling during treatment. A reaction can also develop after you return home. Seek immediate advice for new symptoms after administration; severe breathing difficulty or collapse needs emergency care.

The injection area can become sore, swollen or change colour. Tell the nurse about local changes; spreading redness, increasing pain or fever needs prompt advice. Sites are rotated to reduce irritation.

A painful rash with blisters, peeling, mouth or eye sores, fever or facial swelling can represent a serious drug reaction. Get immediate medical assessment and advice before another lenalidomide dose. Do not treat this as ordinary dry skin.

Blood clots and circulation

Lenalidomide with dexamethasone increases clot risk. A clot can cause a painful swollen limb or travel to the lungs. Arterial clots can cause a heart attack or stroke. Take prescribed clot prevention consistently, but remember that symptoms still need assessment even while taking it. Prevention depends on clotting and bleeding risks.

Liver, kidney and other changes

Yellow eyes or skin, dark urine, much less urine, increasing swelling or persistent vomiting need prompt advice. Tests help distinguish a treatment effect from myeloma, dehydration or infection. People with previous hepatitis B may need monitoring during treatment and for at least six months afterwards.

Rarely, rapid breakdown of cancer cells disturbs blood salts and kidney function, called tumour lysis syndrome. The team assesses this risk and may prescribe preventive treatment. New confusion, severe weakness, cramps, reduced urine or palpitations require urgent assessment.

Lenalidomide treatment is associated with an increased risk of some second cancers. The team weighs this against myeloma control; keep recommended screening and report persistent new changes.

Longer steroid exposure can weaken bones and muscles, affect the eyes and suppress the body's natural steroid production. Severe agitation, hallucinations or depression need prompt medical advice. Report new visual changes, and tell clinicians about steroid treatment before surgery or a serious illness.

Other medicines and vaccinations

Give the pharmacist a complete list, including painkillers, diabetes medicines, blood thinners, digoxin, supplements and Ayurvedic or herbal products. Some medicines increase bleeding, clotting, kidney or muscle risks; others interact with dexamethasone. Do not assume a non-prescription product is harmless.

Do not start aspirin or ibuprofen for pain without checking. Aspirin may separately have been prescribed for clot prevention; if so, do not stop it yourself. The reason for taking a medicine matters.

Discuss vaccinations with your haematology team. Non-live vaccines may be recommended, but protection can be reduced during treatment. Avoid live vaccines unless your specialist specifically confirms that they are suitable. Timing and precautions for household vaccinations depend on the vaccine and your immune status.

Everyday life during treatment

Arrange work, travel and household tasks around your energy and appointments. Avoid driving if sleepy, dizzy, confused or affected by vision problems. An antihistamine before daratumumab may make you drowsy; ask whether someone should take you home.

Use one current calendar. Mark lenalidomide days, steroid days and hospital visits differently. Record doses after taking them and remove superseded instructions.

Tell the team if cost, travel or prescription supply might interrupt treatment. Do not stretch a supply by taking capsules on alternate days unless that is the prescribed schedule. Ask the pharmacy who can help organise the next supply.

People who are pregnant or may be pregnant should not handle lenalidomide capsules or their blister packaging. Caregivers should follow the pharmacist's handling instructions. Never share these medicines, even with another person receiving myeloma treatment.

Fertility, pregnancy and breastfeeding

Lenalidomide can cause severe harm to a developing baby. Pregnancy-prevention counselling, testing and controlled dispensing requirements apply. Your pharmacist must explain the programme relevant to the supplied product; UK, European and US requirements are not identical. Precautions continue during treatment breaks.

For a person who could become pregnant, lenalidomide precautions generally begin four weeks before treatment and continue for four weeks afterwards. US requirements include two acceptable contraceptive methods or the programme's strict abstinence requirements. Pregnancy testing follows the programme's schedule. Daratumumab requires effective contraception during treatment and for three months after its last dose, so obtain a written end date that covers all medicines.

Lenalidomide is present in semen. Condom precautions apply even after vasectomy. US information requires condoms with a pregnant partner or a partner who could become pregnant and prohibits sperm donation during treatment and for four weeks afterwards. European instructions specify at least seven days afterwards and define when condoms are required. Blood-donation restrictions also differ: four weeks after lenalidomide in the US, at least seven days in Europe. Follow your dispensing programme; do not choose the shorter interval yourself.

If you might be pregnant, stop lenalidomide and contact the team immediately. Report a partner's possible pregnancy immediately too. Discuss fertility preservation before treatment if relevant. Do not breastfeed during DRd; ask for advice before breastfeeding afterwards.

After a pause or the end of treatment

Confirm which medicines are paused and whether preventive medicines continue. Do not restart leftover lenalidomide without instruction. A continuing steroid course may require a gradual reduction; the planned days without dexamethasone in your calendar are different from abruptly stopping a prescribed course.

Keep your daratumumab alert card during treatment and for at least six months after the last dose. Tell any hospital or blood bank about daratumumab if a transfusion is considered; interference with blood-matching tests can persist for that period.

Continue follow-up for myeloma, blood counts, persistent side effects and any hepatitis B monitoring arranged. Ask for written end dates for preventive medicines and pregnancy precautions.

Frequently asked questions